Scheduled for June 23 rd the CD19 Vaccine for cancer.
by backoffice | June 15, 2017 9:15 pm
A small company located in Texas will release it’s findings and results
from 110 clinical trials on a treatment centered on a patients immune
system where the T cell will recognize and phagotize the cancer cell.
The release of their findings should lead to licensing fees that should
cause the price of the stock to explode.
Source URL: https://www.stockgumshoe.com/2017/06/microblog-scheduled-for-june-23-rd-the-cd19-vaccine-for-cancer/
This is just now:
BLCM Bellicum Pharmaceuticals Inc $0.20 (1.52%) $20.00 $49.05 (3.82%)
MBRX Moleculin Biotech Inc $0.98 (49.49%) $98.00 $100.05 (51.06%)
So far is good!
Hello Judith, iebought blcm and mbrx, what do you mean ?
Hi! Today unfortunately the BLCM last the earlier gain, the MBRX _2.74%. But this 2 stocks long term holding I think.
It’s amazing how there haven’t been any updates from these people trying to sell their expensive memberships about where they think the stock was going to go to and no response on the 1000% the stock was supposed to go to after the so called announcement from Bellicum after the trials.
Hi! I just cancelled one of their so called membership for $2497,- !!! Yes they are very quiet! But we have here couple of very smart people, luckily they inform us with there blogs, just need to keep up reading.
Any updates on BLCM stock, now that the 23rd. is past?
Its strange and interesting since June 20 – BLCM traded at $12.65 and now its at $11.98, while Moleculin Biotech traded at $1.01 to $2.99 respectively – 200% increase!! I agree .. BLCM maybe a long hold, but got to be watched closely because its a small company.
BLCM bounced around a bit today and looks like they closed at $12.03, off about 10% since I bought it. Looks like it’s going to be a long ride. I hope they strike gold soon!
People bought into that a while back. And then they use you to buy into cap off their profits and then they sell the stock and you’re left with nothing.
I think this is BS. Why announce the. Results in Spain? If the results are so great why did it not make the news?
A look at a 6 month chart for BCLM shows an intermediate term peak about March 21 at $15.50. It has been in a downtrend for the 6 months. This is demonstrated by the stock trend and the On Balance Volume indicator. In other words, while the stock has been aggressively promoted to the public, it appears that insiders have been distributing the stock to the new buyers (errrr, suckers). Last close was at $11.68. You can cast a chart at Stockcharts.com.
A further chart look-back shows the highest high for the year made November 14, 2016 at $23.11. Downhill from there. Today’s last price at $11.70.
See the following article at Yahoo.com Finance:
Here’s Why Bellicum Pharmaceuticals Fell as Much as 13.8% Today
That is how pre-revenue biotechs fund their research and clinical trials. Do you expect a company to just roll over and die when it doesn’t have enough capital . BLCM only has a 27.04 m float so their new offering results in a higher % dilution than if it had a 100 m float. An investors payoff is if the company is successful the stock price will rise and receive a nice pay out. Of course the opposite could happen also. The stock is trading near the lower resistance level of 11.50. This level has also covered the gap up. Now I am waiting to see if it breaks resistance drops or bounces and goes up. Bounces up, I sell. Drops down around 10.50 I buy. There are going to be a lot of ups and downs. At the bottom of the motley fool article there was a bit of good news: The silver lining, if there is one, is that Bellicum Pharmaceuticals does appear to be making headway within its pipeline.
The reality of how start-ups fund their research before earnings is essential to know. It often differs from the great expectations created by promoters who may lead prospective investors to anticipate a trip to the moon at the next company announcement.
AVEO is something to watch!!
Thanks Sal for the head’s up…Pete from Rochester Hills, MI…it’s hard to know which way is up in biotech as I am new to this market segment.
What does Afro stand for?
FYI, we released our Friday File look at this teaser to all readers a few weeks ago: https://www.stockgumshoe.com/reviews/bioscience-millionaire/friday-file-biotech-insider-alert-hints-at-128756-sales-growth-on-june-23/
And yes, it’s BLCM. And yes, the stock is pretty much unchanged a month after the ad started rolling (though the attention from Money Map popped the price up a little bit in late June, the lack of any real revolutionary news brought it back down to where it arguably “belongs”)
Im really curious about this as the ‘small Texas biotech company” that discovered the “missing ingredient” in the “AB4 vaccine just approved by the FDA is being furiously promoted again… is it BLCM?
I was wondering the same thing however, the one they keep talking about seems to work for pediatric hemoglobin. The AB4 as I understood was for pancreatic and prostate cancer. It has been approved by FDA on Aug 30, 2017 for Novartis with Priority Status. I was trying to find out when and where the Phase II study trials were going to be. My husband has Stage 4 Prostate Metastases in the Bones..
Hi PAB,
I’m sorry to hear about your husband’s illness. It is the same company being teased. It looks like they have just expanded trials to include blood cancers (third link below). Perhaps you could contact them directly to find out about Phase 2 studies: I only see a Phase 1 trial ending in April 2017 for prostate/pancreatic cancer.
Kind Regards,
Mary
https://clinicaltrials.gov/ct2/show/NCT02744287?term=BPX-601&rank=1
http://www.bellicum.com/clinical-trials/bpx-601-and-bpx-701/
http://www.bellicum.com/clinical-trials/bpx-501-in-blood-cancers/
I was wondering the same thing because this sounds kind of like the one that you mentioned of AB4 which is the one I was wondering about except they mentioned it had to do with pediatrics hemoglobin cancer and the AB4 concerned the prostate and pancreatic cancer.